Adalimumab

Among patients with rheumatoid arthritis and high baseline interleukin-6, sarilumab was associated with better improvements in physical function and morning stiffness compared with adalimumab, according to data published in Arthritis Research & Therapy.

Ixekizumab showed a significantly higher rate of resolving nail psoriasis compared with adalimumab, according to a study poster presented at the American Academy of Dermatology virtual meeting.

Ixekizumab demonstrated significantly greater joint and skin improvement, through week 52, than adalimumab among patients with psoriatic arthritis, according to data published in the Annals of the Rheumatic Diseases.

Biologic therapies have been proven to significantly change treatment ability and improve the condition of patients with hidradenitis suppurativa, according to a presentation at the Interdisciplinary Autoimmune Summit.

Although patients with rheumatoid arthritis who fail initial TNF therapy are more likely to switch to a second TNF inhibitor, those who swap to a non-TNF-inhibitor are more likely to continue with therapy, researchers reported.

The European Medicines Agency approved the first biosimilar in Europe in 2006. It was almost 10 years before the United States followed. Despite potential savings for payers and patients, biosimilar uptake in the U.S. remains limited.

The FDA has approved the sixth biosimilar to adalimumab, adalimumab-fkjp, for all eligible indications of the biologic product, according to a company press release.

Among patients with rheumatoid arthritis and an inadequate response to methotrexate, high baseline IL-6 may be a prognostic marker of disease progression and severity, and predict better response to sarilumab compared with adalimumab, according to data published in Arthritis & Rheumatology.

A dose reduction schedule of biologics did not show noninferiority to the standard of care based on Psoriasis Area and Severity Index; however, quality of life scores did show noninferiority, according to a clinical trial.

For some patients with inflammatory bowel disease, treatments can be ineffective, and in patients where they do work, they do not always last.